# Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer

> **NCT00063401** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 39 (actual)

## Conditions studied

- Ovarian Cancer
- Peritoneal Neoplasms
- Fallopian Tube Neoplasms

## Interventions

- **BIOLOGICAL:** Cetuximab:
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT00063401
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2006-06
- **Final completion:** 2006-06
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2010-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00063401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00063401, "Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00063401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*